Skip to content

Enterprise value at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$765.76M-9.8%
Viatris logo
ViatrisVTRS
$28.36B+17.7%
PTH
Pelthos Therapeutics Inc.PTHS
$68.17M
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$543.41M+96.3%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$452.74M+5.3%
Opko Health logo
Opko HealthOPK
$918.12M-21.5%

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Cash & equivalents$3.4M-42.2%
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.7%
P/S1.6×+1.0×

Profitability

See full
Gross margin59.7%-12.3pp
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp
FCF margin12.2%

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×
Current ratio0.1×0.0×

Where this comes from

Calculated from Scilex Holding Company’s reported figures.

The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's enterprise value?
Scilex Holding Company (SCLX) reported enterprise value of $138.84M in Q1 2026.
How has Scilex Holding Company's enterprise value changed year-over-year?
Scilex Holding Company's enterprise value increased by 70.9% year-over-year, from $81.25M to $138.84M.
What is the long-term trend for Scilex Holding Company's enterprise value?
Over 4 years (2021 to 2025), Scilex Holding Company's enterprise value has grown at a -39.7% compound annual growth rate (CAGR), from $1.53B to $201.47M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.